<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Adult-<z:e sem="disease" ids="C0341702" disease_type="Disease or Syndrome" abbrv="">acquired Fanconi syndrome</z:e> (FS) is a rare complication of <z:e sem="disease" ids="C1136085" disease_type="Neoplastic Process" abbrv="">monoclonal gammopathy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We retrospectively reviewed 32 patients diagnosed with adult-acquired FS between April 1968 and June 2002 at Mayo Clinic (Rochester, MN) </plain></SENT>
<SENT sid="2" pm="."><plain>At diagnosis, most patients had <z:e sem="disease" ids="C0278494" disease_type="Neoplastic Process" abbrv="MGUS">monoclonal gammopathy of undetermined significance</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MGUS</z:e>) or smoldering <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (SMM), with a median <z:chebi fb="0" ids="16737">creatinine</z:chebi> level of 176.8 microM (2.0 mg/dL; range, 79.56-327.08 microM [0.9-3.7 mg/dL]) and evidence of <z:hpo ids='HP_0002749'>osteomalacia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>During the average 65 months (range, 2-238 months) of follow-up, 5 patients developed <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) and only 1 of 14 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MGUS</z:e> transformed to <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) </plain></SENT>
<SENT sid="4" pm="."><plain>Also, 14 <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred, with only 1 from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> but 4 from alkylator-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Chemotherapy offered little benefit on renal functions of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MGUS</z:e> or SMM patients </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, FS associated with <z:e sem="disease" ids="C1136085" disease_type="Neoplastic Process" abbrv="">monoclonal gammopathy</z:e> does not appear to confer an additional risk of subsequent evolution to MM </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> occurs late in the disease process </plain></SENT>
</text></document>